全文获取类型
收费全文 | 332篇 |
免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
妇产科学 | 11篇 |
基础医学 | 16篇 |
口腔科学 | 7篇 |
临床医学 | 26篇 |
内科学 | 71篇 |
皮肤病学 | 4篇 |
神经病学 | 10篇 |
特种医学 | 6篇 |
外科学 | 19篇 |
综合类 | 1篇 |
预防医学 | 12篇 |
眼科学 | 9篇 |
药学 | 35篇 |
中国医学 | 3篇 |
肿瘤学 | 100篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 3篇 |
2019年 | 10篇 |
2018年 | 15篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 22篇 |
2014年 | 21篇 |
2013年 | 24篇 |
2012年 | 40篇 |
2011年 | 34篇 |
2010年 | 21篇 |
2009年 | 11篇 |
2008年 | 37篇 |
2007年 | 13篇 |
2006年 | 12篇 |
2005年 | 19篇 |
2004年 | 12篇 |
2003年 | 5篇 |
2002年 | 6篇 |
2001年 | 1篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1989年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有334条查询结果,搜索用时 16 毫秒
331.
Summary
Background: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC.
Methods: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve. Patients received arsenic trioxide 0.16–0.24 mg/kg per day for 5–6 days per week for 3–4 weeks, followed by one-week rest. Tumor response was assessed every 2 cycles. Primary endpoint was the percentage of patients with 6-month disease stabilization.
Results: Twenty-nine patients (median age, 59) with locally advanced or metastatic HCC received a total of 61 cycles (median, 2; range, 1–6). One patient had partial response. Three patients had disease stabilization for at least six months. The 6-month tumor stabilization rate was 14% (95% CI, 1–27). The median overall survival was 4.8 months (95% CI, 1.4–8.2) and one-year survival was 30%.
Conclusion: Single-agent arsenic trioxide using this dose schedule is not active against advanced HCC. 相似文献
332.
Chun-Yin Huang Yi-Chin Fong Chun-Yi Lee Hsiao-Chi Tsai Chih-Hsin Tang 《Biochemical pharmacology》2009,77(5):794-15297
CCL5 (previously called RANTES) is in the CC-chemokine family and plays a crucial role in the migration and metastasis of human cancer cells. Besides, integrins are the major adhesive molecules in mammalian cells. Here we found CCL5 increased the migration and cell surface expression of αvβ3 integrin in human lung cancer cells (A549 cells). CCL5 stimulation increased phosphorylation of the p85α subunit of phosphatidylinositol 3-kinase (PI3K) and serine 473 of Akt. Also, we found that PI3K inhibitor (Ly294002) or Akt inhibitor suppressed CCL5-induced migration activities and integrin expression of A549 cells. Transfection of cells with p85 or Akt mutant also reduced CCL5-mediated cancer migration. In addition, treatment of A549 cells with CCL5 induced IκB kinase α/β (IKK α/β) phosphorylation, IκB phosphorylation, p65 Ser536 phosphorylation, and κB-luciferase activity. Furthermore, the CCL5-mediated increases in p65 Ser536 phosphorylation were inhibited by Ly294002 and Akt inhibitor. Taken together, our results suggest that CCL5 acts through PI3K/Akt, which in turn activates IKKα/β and NF-κB, resulting in the activation of αvβ3 integrin and contributing to the migration of human lung cancer cells. 相似文献
333.
Chen YM Yu CJ Yang CH Perng RP Tsai CM Shih JF Cheng AL Lefresne F Barbier M Pouget JC Yang PC 《Lung cancer (Amsterdam, Netherlands)》2007,56(1):89-95
BACKGROUND: Intravenous vinorelbine plus cisplatin is widely prescribed for the treatment of NSCLC. The objective of this phase II study was to define the efficacy of an oral form of vinorelbine combined with cisplatin for first line treatment of advanced/metastatic NSCLC. PATIENTS AND METHODS: From September 2002 to December 2003, 46 chemotherapy-naive patients received 80 mg/m(2) of cisplatin on day 1 and oral vinorelbine at 60 mg/m(2) on days 1 and 8, every 3 weeks. RESULTS: After an independent panel review, the response rate was 37.5 % [95% confidence interval (CI): 22.7-54.2%] in the evaluable population and 32.6% [95% CI: 19.5-48] in the intent-to-treat population. Median progression-free survival was 5.6 months and overall survival was 11.2 months. Grades 3 and 4 neutropenia was observed in 58.7% of patients, with febrile neutropenia and neutropenic infection in 4.3 and 8.7% of patients, respectively. The main non-haematological toxicities were hypotension, fatigue (8.7% for each) and gastrointestinal disorders with rare grades 3 and 4. CONCLUSIONS: These results suggest that the combination of cisplatin at 80 mg/m(2) on day 1 with oral vinorelbine at 60 mg/m(2) on days 1 and 8, every 3 weeks, is an active regimen, associated with acceptable toxicity. Oral vinorelbine is therefore a good alternative to the i.v. formulation. 相似文献
334.